ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From Biomechanics to Metallobiology: A Bibliometric Mapping of Ferroptosis and Trace Elements in Osteoarthritis (2014-2024).Biological trace element research · 2026Article
- Cellular signaling crosstalk between osteoporosis and diabetes: Common mechanisms and therapeutic targets (Review).Biomedical reports · 2026Review
- Intelligence-responsive wettability switch coating on magnesium implants for treating osteoporotic fracture.Nature communications · 2026Article
- Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss.Journal of cellular and molecular medicine · 2026Review
- The role and mechanisms of bone microenvironment regulators in osteoporosis: novel intervention strategies for addressing the challenges of aging.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclear factor erythrocyte 2-related factor-2 (Nrf2) signaling pathway is an important regulatory factor for bone homeostasis in osteoporosis. It is also regarded as a key pathway of antioxidant stress and is closely related to the pathological process of osteoporosis. Osteoporosis is a chronic metabolic bone disease characterized by an imbalance between osteoclast bone resorption and osteoblast bone formation, and oxidative stress is the core driving factor that induces bone metabolic imbalance. Studies have confirmed that the Nrf2 signaling pathway plays a key role in the pathological process of osteoporosis and in maintaining the homeostasis of the bone microenvironment. Here, we review the current knowledge about the role of the Nrf2 signaling pathway in osteoporosis and analyze its interaction with bone metabolism-related signaling pathways such as Wnt/β-catenin and NF-κB. By systematically integrating the existing research evidence, the therapeutic value of targeted activation of Nrf2 in improving bone metabolic imbalance, inhibiting osteoclastic activity and promoting bone formation is reviewed. Multiple studies have shown that the Nrf2 pathway, as a core antioxidant mechanism, effectively inhibits the excessive activation of osteoclasts and hyperresorption by antagonizing oxidative stress in osteoporosis, and dynamically regulates bone homeostasis. It forms a cross-regulatory network with key signaling pathways such as Wnt/β-catenin (promoting bone formation) and NF-κB (promoting inflammation), jointly influencing the level of oxidative stress and the balance of bone remodeling. Importantly, targeted activation of Nrf2 demonstrates significant therapeutic potential, capable of simultaneously promoting bone formation, inhibiting osteoclastic activity, and restoring the dynamic balance of bone metabolism, thereby providing multi-dimensional intervention in the pathological process of osteoporosis. The Nrf2 signaling pathway plays a core protective role in the pathogenesis of osteoporosis by regulating oxidative stress and related pathological links in multiple dimensions. Its interaction with key bone metabolic pathways provides a theoretical basis for the development of therapeutic strategies targeting Nrf2 and is expected to become a novel therapeutic target for improving bone metabolic imbalance.
Indexed as
Identifiers
40663116What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.